TIDMPRTC
PureTech Health PLC
23 August 2016
23 August 2016
PureTech Health plc
PureTech's Vedanta Biosciences Granted Second U.S. Patent
Covering Methods of Treating Autoimmune Disease with Therapeutics
Based on Bacterial Consortia
PureTech Health plc ("PureTech", LSE: PRTC), a
cross-disciplinary biotech company developing 21(st) century
medicines in and at the interface of the brain, gut and immune
system, is pleased to note that the United States Patent and
Trademark Office (USPTO) has issued a second U.S. Patent to Vedanta
that broadly covers methods of treating autoimmune disease with
mixtures of Clostridium live bacterial strains. U.S. Patent No.
9,415,079 further expands Vedanta's patent portfolio after the
issuance of US 9,415,079 on 16 August and earlier issuances in
Japan. The patents are exclusively licensed to Vedanta under an
agreement with the University of Tokyo and provide coverage through
at least 2031.
Daphne Zohar, Co-Founder and Chief Executive Officer at
PureTech, said: "This second U.S. patent further strengthens our IP
leadership position in the microbiome space and underscores our
commitment to advancing new modalities to address disease."
The full text of the announcement from Vedanta is as
follows:
Vedanta Biosciences Granted Second U.S. Patent Covering Methods
of Treating Autoimmune Disease with Therapeutics Based on Bacterial
Consortia
CAMBRIDGE, Massachusetts, August 23, 2016 - Vedanta Biosciences,
pioneering the development of a novel class of therapies designed
to modulate pathways of interaction between the human microbiome
and the host immune system, today announced that the United States
Patent and Trademark Office (USPTO) has issued U.S. Patent No.
9,421,230. The patent broadly covers methods of treating autoimmune
disease with mixtures of Clostridium live bacterial strains and
further expands Vedanta's patent portfolio after the issuance of US
9,415,079 on August 16 and earlier issuances in Japan. The patents
are exclusively licensed to Vedanta under an agreement with the
University of Tokyo and provide coverage through at least 2031.
The patented technology is based on ground-breaking work by Dr.
Kenya Honda, a scientific co-founder of Vedanta. Dr. Honda's work
shows that compositions of bacterial strains belonging to
Clostridium clusters IV and/or XIVa may potentially be used to
treat a range of autoimmune diseases, such as ulcerative colitis,
Crohn's disease or graft versus host disease.
"We believe this second U.S. patent, together with the
composition of matter patent recently issued in the same family,
reinforces Vedanta's IP leadership position in the microbiome
field," said Bernat Olle, Ph.D., Chief Executive Officer of
Vedanta. "The patent broadly covers the treatment of autoimmune
diseases with compositions of bacterial consortia belonging to
Clostridium clusters IV and/or XIVa, and it further strengthens our
ability to build value from our IP estate via internal programs and
strategic alliances."
About Vedanta
Vedanta Biosciences is pioneering development of a novel class
of therapies designed to modulate pathways of interaction between
the human microbiome and the host immune system, with clinical
trials in certain indications expected to begin in the first half
of 2017. Founded by PureTech Health (PureTech Health plc, PRTC.L)
and a group of world-renowned experts in immunology and
microbiology, Vedanta Biosciences is a leader in the microbiome
field with capabilities to discover, develop and manufacture drugs
based on live commensal microbes. Leveraging its proprietary
technology platform and the expertise of its team of scientific
cofounders, Vedanta Biosciences has isolated a vast collection of
human-associated bacterial strains and characterised how the immune
system recognises and responds to these microbes. This work has led
to the identification of human commensal bacteria that induce a
range of immune responses - including induction of regulatory T
cells and Th17 cells, among others - as well as the
characterisation of novel molecular mechanisms of microbial-host
communication. These advances have been published in leading
peer-reviewed journals including Science, Nature (multiple), Cell
and Nature Immunology. Vedanta has harnessed these biological
insights as well as data from clinical translational collaborations
to generate a pipeline of programs in development for infectious
disease, autoimmune disease, inflammation and immune-oncology. The
clinical potential of therapeutic manipulation of the microbiome
has been validated by multiple randomised, controlled trials in
infectious disease and inflammatory bowel disease.
Vedanta's scientific co-founders have pioneered the fields of
innate immunity, Th17 and regulatory T cell biology, and include
Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr.
Alexander Rudensky (tri-institutional Professor at the Memorial
Sloan-Kettering Institute, the Rockefeller University and Cornell
University), Dr. Dan Littman (Professor of Molecular Immunology at
NYU), Dr. Brett Finlay (Professor at the University of British
Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio
University).
PureTech Health plc (PRTC.L) owns 75.4% of the company on a
diluted basis as of 6 June 2016. This calculation includes issued
and outstanding shares as well as options to purchase shares and
written commitments to issue shares or options, but excludes
unallocated shares authorised to be issued pursuant to equity
incentive plans.
About PureTech Health
PureTech Health (PureTech Health plc, PRTC.L) is a
cross-disciplinary biotech company focused on areas of growing
scientific and technical insights that it believes are at an
important inflection point, including the central nervous,
gastro-intestinal and immune systems, and the interactions and
signalling between them. PureTech has approximately 20 clinical
studies across its pipeline targeting multi-billion dollar market
opportunities, including five human proof-of-concept studies and
multiple pivotal or registration study readouts expected in the
next two years. While inevitably some technologies will not advance
to commercialisation, PureTech's approach mitigates risk as most of
the cash resides on a PureTech parent company level, allowing
PureTech to build value and divert cash to its most successful
programmes as milestones are achieved. PureTech has over 220
patents and patent applications. PureTech's leading team and board,
along with an advisory network of more than 60 expert
founder-scientists and advisors across multiple disciplines, gives
PureTech access to potentially ground-breaking science and
technological innovation. With healthcare undergoing major
transformation, PureTech believes it is well positioned to develop
and launch medicines for the 21st century. For more information,
visit www.puretechhealth.com and connect with us on Twitter.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Enquiries
PureTech
Allison Mead, Director, Communications +1 617 651
and Investor Relations 3156
FTI Consulting (Communications adviser
to PureTech)
Ben Atwell +44 (0) 20
Matthew Cole 3727 1000
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADLLFLQVFLBBF
(END) Dow Jones Newswires
August 23, 2016 02:00 ET (06:00 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024